中研2号治疗HIV/AIDS的临床和实验研究

目的：观察中研2号对HIV／AIDS患者和猴艾滋病毒SIV mac25l感染猴的疗效，评价该方抗艾滋病毒和对机体的保护作用。方法：根据统一的诊断标准，对确诊的HIV／AIDS患者给予中研2号治疗，疗程为3个月，从免疫功能、病毒载量和临床症状体征等方面进行疗效判定；采用猴艾滋病模型，以病毒分离、酶联免疫法及流式细胞仪检测SIV水平、CD4^+、CD8^+细胞及新喋呤水平，并进行病理学检查。结果：中研2号对治疗HIV／AIDS患者临床有效率为45％～55％；对猴艾滋病模型不仅能降低感染猴病毒血症及SIV p27抗原水平，同时能持续提高CD4^+细胞数量，降低血清新喋呤含量，与叠氮胸苷阳性药对照结果近似，与生理盐水比较，差异有显著性。病理检查显示中研2号能激活并促进淋巴结中心细胞的增殖。结论：中研2号具有一定的临床效果，可抑制感染猴血浆病毒血症及保护机体免疫功能。

Clinical and Experimental Study on Treatment of HIV/AIDS Patients by Zhongyan No.2

Objective: To investigate the therapeutic effect of Zhongyan No. 2 (ZY-2) in treating HIV/AIDS patients and SIVmac 251 infection in macaques, and to evaluate its effects in antagonizing HIV and protecting organism. Methods: Forty-four patients with HIV/AIDS from China and Tanzania, whose diagnosis conformed with the same standard were observed clinically for 3 months. The therapeutic effect was evaluated in terms of immune function, viral load, and clinical symptoms and signs. Using SIVmac251 monkey model to detect the plasma SIV p27 level by viral isolation and ELISA; to determine the T-lymphocytes subsets CD4+ and CD8+ by flow cy-tometry, and the level of neopterin was measured by ELISA. The pathological examination was conducted also. Results: ZY-2 showed a clinical effective rate of 45 % ~ 55 % in treating HIV/AIDS, it could not only lower the viremia in infected monkey, and plasma SIV p27 antigen level, but also increase the CD4+ count continuously and lower the serum content of neopterin to the level approaching those in the positive control group treated with AZT and showed significant difference as compared with those in the negative control group. Pathological examination showed that ZY-2 could activate and promote the cell proliferation in central region of lymphnodes. Conclusion: ZY-2 has clinical effect in inhibiting the viremia in infected monkey and enhancing the immunity of HIV/AIDS patients.